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A B S T R A C T
Background
Infection with hepatitis B virus (HBV) can be symptomatic or asymptomatic. Apart from chronic HBV infection, the complications
related to acute HBV infection are severe acute viral hepatitis and fulminant hepatitis characterised by liver failure. The optimal
pharmacological treatment of acute HBV infection remains controversial.
Objectives
To assess the benefits and harms of pharmacological interventions in the treatment of acute HBV infection through a network meta-
analysis and to generate rankings of the available treatments according to their safety and efficacy. As it was not possible to assess whether
the potential effect modifiers were similar across different comparisons, we did not perform the network meta-analysis, and instead,
assessed the benefits and harms of different interventions using standard Cochrane methodological procedures.
Search methods
We searchedCENTRAL,MEDLINE,Embase, ScienceCitation IndexExpanded,WHOInternationalClinical TrialsRegistry Platform,
and randomised clinical trials (RCTs) registers to August 2016 to identify RCTs on pharmacological interventions for acute HBV
infection.
Selection criteria
RCTs, irrespective of language, blinding, or publication status in participants with acuteHBV infection.We excluded trials if participants
had previously undergone liver transplantation and had other coexisting viral diseases such as hepatitis C virus and HIV.We considered
any of the various pharmacological interventions compared with each other or with placebo, or no intervention.
Data collection and analysis
We calculated the odds ratio (OR) and rate ratio with 95% confidence intervals (CI) using both fixed-effect and random-effects models
based on available-participant analysis with Review Manager 5. We assessed risk of bias, controlled risk of random errors with Trial
Sequential Analysis, and assessed the quality of the evidence using GRADE.
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Main results
Seven trials (597 participants) met our review inclusion criteria. All trials provided information for one or more outcomes; however,
five participants were excluded from analysis by study authors. All the trials were at high risk of bias. Overall, all the evidence was low
or very low quality evidence because of risk of bias (downgraded one level for risk of bias), small sample size (downgraded one level
for imprecision), and wide CIs (downgraded one more level for imprecision in some comparisons). Of the seven trials, six were two-
armed trials, while one trial was a three-armed trial. The comparisons included hepatitis B immunoglobulin (HBIG) versus placebo
(one trial; 55 participants); interferon versus placebo (two trials; 200 participants); lamivudine versus placebo or no intervention (four
trials; 316 participants); lamivudine versus entecavir (one trial; 90 participants); and entecavir versus no intervention (one trial; 131
participants). One trial included only people with acute HBV with hepatic encephalopathy (i.e. people with fulminant liver failure);
one trial included only people with severe acute HBV, but it did not state whether any of the people also had fulminant HBV infection;
three trials excluded fulminant HBV infection; and two trials did not report the severity of acute HBV infection. The mean or median
follow-up period in the trials ranged from three to 12 months in the trials that provided this information.
There was no evidence of any differences in short-term mortality (less than one year) in any of the comparisons: HBIG versus placebo
(OR 1.13, 95% CI 0.36 to 3.54; participants = 55; 1 trial), lamivudine versus placebo or no intervention (OR 1.29, 95% CI 0.33
to 4.99; participants = 250; 2 trials); lamivudine versus entecavir (OR 1.23, 95% CI 0.13 to 11.65; participants = 90; 1 trial), or
entecavir versus no intervention (OR 1.05, 95% CI 0.12 to 9.47; participants = 131; 1 trial). The proportion of people who progressed
to chronic HBV infection was higher in the lamivudine group than the placebo or no intervention group (OR 1.99, 95% CI 1.05 to
3.77; participants = 285; 3 trials) and in the lamivudine group versus entecavir group (OR 3.64, 95% CI 1.31 to 10.13; participants
= 90; 1 trial). There was no evidence of a difference in the proportion of people who progressed to chronic HBV infection between
the entecavir and the no intervention groups (OR 0.58, 95% CI 0.23 to 1.49; participants = 131; 1 trial). None of the trials reported
progression to fulminant HBV infection. Three trials with 371 participants reported serious adverse events. There were no serious
adverse events in any of the groups (no intervention: 0/183 (0%), interferon: 0/67 (0%), lamivudine: 0/100 (0%), and entecavir: 0/21
(0%)). The proportion of people with adverse events was higher in the interferon group than the placebo group (OR 348.16, 95% CI
45.39 to 2670.26; participants = 200; 2 trials). There was no evidence of a difference in the proportion of people with adverse events
between the lamivudine group and the placebo or no intervention group (OR 1.42, 95% CI 0.34 to 5.94; participants = 35; 1 trial)
or number of adverse events between the lamivudine group and the placebo or no intervention group (rate ratio 1.72, 95% CI 1.01
to 2.91; participants = 35; 1 trial). One trial with 100 participants reported quality of life at one week. The scale used to report the
health-related quality of life was not stated and lacked information on whether higher score meant better or worse, making it difficult
to interpret the results. None of the trials reported quality of life beyond one week or other clinical outcomes such as mortality beyond
one year, liver transplantation, cirrhosis, decompensated cirrhosis, or hepatocellular carcinoma.
Two trials received funding from pharmaceutical companies; three trials were funded by parties without any vested interest in the results
or did not receive any special funding; the source of funding was not available in the remaining two trials.
Authors’ conclusions
Low or very low quality evidence suggests that progression to chronic HBV infection was higher in people receiving lamivudine
compared with placebo, no intervention, or entecavir. Low quality evidence suggests that interferonmay increase the adverse events after
treatment for acute HBV infection. Based on a very low quality evidence, there is currently no evidence of benefit of any intervention
in acute HBV infection. There is significant uncertainty in the results and further RCTs are required.
P L A I N L A N G U A G E S U M M A R Y
Medical treatment of acute hepatitis B virus infection
Background
Hepatitis B virus (HBV) is a virus that affects the liver. It is usually transmitted by injectable drug abuse, transfusion of infected blood,
unhygienic tattooing practices, coming into contact with blood infected with HBV, or by unprotected sex. Acute HBV infection is
the period that covers the period immediately after HBV infection. Most people are asymptomatic. About 5% to 40% of people with
acute HBV develop symptoms such as jaundice (yellowish discolouration of the eyes and skin), tummy pain, tiredness, nausea, and
vomiting. While most people clear the virus after acute HBV infection, the virus remains in others (chronic HBV infection) and causes
major health problems (excessive tiredness and eventually may end with liver failure leading to vomiting blood, confusion, and death).
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Occasionally, people with acute HBV may develop immediate liver failure (fulminant HBV infection). The best way to treat acute
HBV is not clear. We sought to resolve this issue by performing this review. We included all randomised clinical trials (RCTs) (clinical
studies where people are randomly put into one of two or more treatment groups) published to August 2016. We included only trials in
which participants with acute HBV infection had not undergone liver transplantation previously and did not have liver disease due to
other viral infections. Apart from using standard Cochrane methods which allow comparison of only two treatments at a time (direct
comparison), we planned to use an advanced method which allows comparison of the many different treatments individually which are
compared in the trials (network meta-analysis). However, because of the nature of the information available, we could not determine
whether the network meta-analysis results were reliable. So, we used standard Cochrane methodology.
Study characteristics
We identified seven RCTs. Trial authors included 592 (out of 597 randomised) participants in analyses. The trials included people with
acute HBV infection of varying severity. The main interventions included hepatitis B immunoglobulin (a vaccine), interferon (protein
secreted in response to viral infection), and lamivudine and entecavir (medicines) which are considered to have antiviral effects and
were compared with placebo or no intervention. The trials’ average follow-up period ranged from three months to one year in the six
trials that reported this information.
Two trials received funding from pharmaceutical companies; three trials were funded by parties without any vested interest in the results
or did not receive any special funding; two trials did not report the funding source.
Quality of evidence
The overall quality of evidence was low or very low, and all the trials were at high risk of bias (the likely possibility of making wrong
conclusions overestimating benefits or underestimating harms because of the way the studies were conducted is high).
Key results
There was no evidence of differences in death at less than one year between any of the treated and untreated groups. The percentage
of people who progressed to chronic HBV infection was higher in lamivudine versus placebo or no intervention and lamivudine versus
entecavir groups. There was no evidence of difference in the proportion of people who progressed to chronic HBV infection between
entecavir and no intervention. None of the trials reported progression to fulminant HBV infection. There were no serious adverse
events in any of the treatment groups in the trials that reported this information. The percentage of people who developed adverse
events was higher in the interferon group (100%) than in the placebo (dummy treatment) group (27%) in the trials that reported this
information. There was no evidence of differences in the percentage of people who developed adverse events or the total number of
adverse events in the comparison between lamivudine versus no treatment. One trial reported quality of life at one week; however, the
information provided was insufficient to determine whether there was any difference between the interferon and placebo groups. None
of the trials reported quality of life beyond one week or other important outcomes such as death beyond one year, severe progressive liver
damage, liver failure, requirement for liver transplantation, or liver cancer. There is currently no evidence of benefit of any treatment
in acute HBV infection. There is significant uncertainty in the results and high-quality RCTs are required.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Lamivudine versus no intervention for acute hepatitis B virus infection
Patient or population: people with acute HBV infect ion
Settings: secondary or tert iary care
Intervention: lam ivudine
Control: no intervent ion
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(trials)
Quality of the evidence
(GRADE)
Assumed risk Corresponding risk
No intervention Lamivudine
Short- term mortality (< 1
year)
33 per 1000 43 per 1000
(11 to 147)
OR 1.29
(0.33 to 4.99)
250
(2 trials)
⊕©©©
Very low1,2,3
Progression to chronic HBV
infection (6 to 12 months)
413 per 1000 584 per 1000
(425 to 726)
OR 1.99
(1.05 to 3.77)
285
(3 trials)
⊕©©©
Very low1,2,3
Progression to fulminant
HBV infection
None of the trials reported this information.
Serious adverse events (6
to 12 months)
There were no serious adverse events in either group. 250
(2 trials)
⊕©©©
Very low1,2,3
Adverse events (propor-
tion) (12 months)
647 per 1000 722 per 1000
(384 to 916)
OR 1.42
(0.34 to 5.94)
35
(1 trial)
⊕©©©
Very low1,2,3
Adverse events (number of
events) (12 months)
1235 per 1000 2124 per 1000
(1247 to 3594)
Rate ratio 1.72
(1.01 to 2.91)
35
(1 trial)
⊕©©©
very low1,2,3
Health- related quality of
life (1 week)
None of the trials reported this information.
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* The basis for the assumed risk is the mean control group risk in the control group across studies. The corresponding risk (and its 95% conf idence interval) is based on the
assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
CI: conf idence interval; HBV: hepat it is B virus; OR: odds rat io.
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1 The risk of bias in the trial(s) was high (downgraded by 1 level for risk of bias).
2 The sample size was small (downgraded by 1 level for imprecision)
3 The conf idence intervals were wide (downgraded by 1 level for imprecision).
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B A C K G R O U N D
Description of the condition
Hepatitis B virus (HBV) is amember of theHepadnaviridae (hepa-
totropicDNA virus) family, a family of viruses that infect liver cells
(Ganem 2004). Currently, 10 HBV genotypes (genotypes A to J)
are recognised (Lin 2011;Tanwar 2012). Themajormode of trans-
mission of HBV is by parenteral routes, which include parenteral
drug abuse, transfusion of infected blood, unhygienic tattooing
practices, and occupational exposure to the blood of people in-
fected with HBV (Wright 1993; Thompson 2009; Nelson 2011).
The other major modes of transmission include sexual intercourse
with infected people and perinatal transmission from mother to
child (Wright 1993; Shi2010;Deng 2012). The incubationperiod
of HBV infection is about two to four weeks (Tillmann 2014). In-
fection with HBV is usually self-limiting and can be symptomatic
(jaundice, abdominal pain, fatigue, nausea, and vomiting) in about
5% to 40% of people or asymptomatic (Leen 1989; Ganem 2004;
Kumar 2006; Choi 2011; Sharif 2013; Tillmann 2014). Acute
HBV infection is usually followed by spontaneous clearance of
the virus and long-lasting protection against reinfection (Ganem
2004; Choi 2011; Tillmann 2014). Acute HBV infection can be
difficult to distinguish from first exacerbation of asymptomatic
chronic HBV, despite serological tests (Kumar 2006). Apart from
chronic HBV infection, the complications related to acute HBV
infection are severe acute HBV and fulminant hepatitis charac-
terised by liver failure. Severe acute HBV is variably defined as the
presence of at least two of the following criteria: severe jaundice
(bilirubin levels higher than 10 mg/dL or 171 µmol/L), interna-
tional normalised ratio (INR; an expression of the blood’s ability
to clot) of 1.6 or greater, hepatic encephalopathy (Bruno 2014),
or the presence of elevated transaminase levels along with an ele-
vated INR (Tillmann 2014). Fulminant hepatitis is characterised
by liver failure manifest as elevated INR and hepatic encephalopa-
thy (Tillmann 2014).
In the US, approximately 3000 people developed acute HBV in-
fection annually between 2010 and 2014, equating to about 1 in
100,000 population with highest rates in the 30- to 39-year age
group and lowest rates in children and adolescents (CDC 2014).
The incidence is higher in men than women (CDC 2014).
The proportion of people with fulminant hepatitis after an attack
of acute HBV can be variable, depending upon whether all people
with acute HBV infection are included in the analysis (2% of peo-
ple with acute HBV becoming fulminant) or whether only those
people with severe acuteHBV infection are included in the analysis
(4% to 5% of people with severe acute HBV becoming fulminant)
(Leen 1989; Souza 2013; Coppola 2014). A significant proportion
of people with fulminant hepatitis B require liver transplantation
or may die (varies from 18% to 48%) (Leen 1989; Garfein 2004;
Tillmann 2006). Overall, approximately 1% of people with acute
HBV (of all severities) died (CDC 2014).
Less than 1% to 27% of people develop chronic HBV infection
(persistence of acute HBV infection for more than six months)
(Ganem 2004; McMahon 2014; Tillmann 2014). The risk of
chronic HBV infection can be as high as 90% if the primary,
acute HBV infection occurs at birth and 25% if it occurs between
early infancy and five years of age (McMahon 2014). Later in life,
the risk declines. Overall, in people with chronic HBV infection,
about 13.5%develop cirrhosis (Yang 2009), and about 5%develop
hepatocellular carcinoma (Hoofnagle 2007; Thiele 2014). People
with compensated (asymptomatic) chronic HBV-related cirrhosis
may develop decompensated (symptomatic) cirrhosis (3% to 5%
per year), or hepatocellular carcinoma (2% to 8% per year), or die
(3% to 4% per year) (Chu 2006).
Description of the intervention
Various drugs, such as nucleoside or nucleotide analogues (L-nu-
cleosides (lamivudine, telbivudine, clevudine), acyclic phospho-
nates (adefovir, tenofovir), and cyclopenteanes (entecavir)), N-
acetyl cysteine, ursodeoxycholic acid, interferon, and thymosin,
have been used to prevent the complications of acute HBV in-
fection and progression to chronic HBV infection (Bruno 2014;
Tillmann 2014). Nucleoside analogues and nucleotide analogues
are administered orally (Martindale 2011). N-acetyl cysteine is
an antioxidant that can be administered orally or intravenously
(Martindale 2011; Bass 2013). Ursodeoxycholic acid is a bile salt
that is administered orally (Lazaridis 2001; Martindale 2011). In-
terferons are proteins secreted by cells in response to a wide range
of inducers and that confer resistance against viruses and can-
cer cells (NCBI 2014a). The major types of interferon include
interferon-alpha (or interferon-alfa), interferon-beta, interferon-
omega, interferon-lambda, and interferon-gamma (Feld 2005;
NCBI 2014a). Interferon-alpha is used in acute HBV infection
(Tassopoulos 1997). Interferon is usually manufactured by recom-
binant technology where a sequence of human DNA is combined
with the DNA of a bacteria such as Escherichia coli (Anonymous
1981). A variation of interferon-alpha is pegylated interferon-
alpha, where the structure of interferon is modified to make it
long acting (Bailon 2001). Interferon-alpha is usually administered
by subcutaneous or intramuscular injections (Martindale 2011).
Thymosins are a family of polypeptide hormones secreted by the
thymus gland (NCBI 2014b). Thymosin-alpha (or thymalfasin)
is usually manufactured by recombinant technology and is ad-
ministered subcutaneously (Li 2010; Martindale 2011). It should
be noted that these treatments have significant complications in-
cluding severe infections, anaemia, neutropenia, thrombocytope-
nia, renal impairment, and neuropsychiatric disorders (homici-
dal and suicidal ideas) (Martindale 2011). Other complications
include abdominal pain, elevation of liver enzymes, and myalgia
(Martindale 2011).
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How the intervention might work
Nucleoside and nucleotide analogues inhibit viral replication by
inhibiting reverse transcriptase (ribonucleic acid (RNA)-directed
DNA polymerase) in different ways (Martindale 2011). N-Acetyl
cysteine increases the levels of glutathione, which is an antioxi-
dant and protects the cells against oxidative stress. In addition, N-
acetyl cysteine increases nitric oxide production resulting in va-
sodilation and improved tissue oxygen delivery and uptake, and
inhibits proinflammatory factors (Bass 2013). Ursodeoxycholic
acid decreases the exposure of liver cells to toxic bile salts and has
anti-inflammatory properties (Bass 2013). This may decrease the
damage to the liver cells. Interferon is one of the natural defence
mechanisms of the body against viruses (Feld 2005;NCBI 2014a).
Interferons induce interferon-stimulated genes, which creates an
antiviral state within the cells (Feld 2005). Thymosins increase
lymphocyte production and enhance the function of T cells (Li
2010; NCBI 2014b).
Why it is important to do this review
The current guidelines on the management of acute HBV infec-
tion by the EuropeanAssociation for the Study of the Liver (EASL)
recommends the following treatment (EASL 2012). Entecavir or
tenofovir should be used in people with acute severe HBV infec-
tion or people with fulminant hepatitis. Antiviral therapy should
be continued for at least three months after the appearance of anti-
HBs (antibody against HBsAg, the surface antigen of HBV) or at
least 12 months after appearance of anti-HBe (antibody against
HBeAg, a protein secreted by virus). However, the American As-
sociation for the Study of Liver Diseases (AASLD) guidelines rec-
ommend treatment only in people with fulminant hepatitis and
in people with protracted severe acute HBV infection (AASLD
2009). Lamivudine and telbivudine may be used when the antic-
ipated duration of treatment is short; otherwise, entecavir is the
preferred treatment (AASLD 2009). Treatment should be contin-
ued until the clearance of HBsAg or indefinitely in people un-
dergoing liver transplantation (AASLD 2009). Interferon-alpha is
contraindicated in acute HBV infection (AASLD 2009). Thus,
the optimal management of people with acute HBV infection is
not known.
Network meta-analysis allows combining the direct evidence and
indirect evidence and allows ranking of different treatments in
terms of the different outcomes (Salanti 2011; Salanti 2012).
There has been no network meta-analysis on the pharmacologi-
cal interventions used for treatment of acute HBV infection. This
systematic review and attempted network meta-analysis intended
to provide the best level of evidence for the role of different phar-
macological interventions in the treatment of people with acute
HBV infection.
O B J E C T I V E S
To assess the comparative benefits and harms of different pharma-
cological interventions in the treatment of acute HBV infection
through a network meta-analysis and to generate rankings of the
available pharmacological interventions according to their safety
and efficacy. However, it was not possible to assess whether the po-
tential effect modifiers were similar across different comparisons.
Therefore, we did not perform the network meta-analysis, and
assessed the benefits and harms of different interventions using
standard Cochrane methodology.
When more trials become available with adequate description of
potential effect modifiers, we will attempt to conduct network
meta-analysis to generate rankings of the available interventions
according to their safety and efficacy. This is why we retain the
planned methodology for network meta-analysis in our Appendix
1. Once data appear allowing for the conduct of network meta-
analysis, this Appendix 1 will be moved back into the Methods
section.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We considered only randomised clinical trials for this systematic
review irrespective of language, publication status, or date of pub-
lication. We excluded studies of other designs because of the risk
of bias in such studies. We are all aware that such exclusions make
us focus much more on potential benefits and not fully assess the
risks of serious adverse events as well as risks of adverse events.
Types of participants
We included participants with acute HBV infection irrespective of
the presence or absence of symptoms, severity of the HBV infec-
tion, method of diagnosis of the disease, or HBV genotype.We ex-
cluded participants who had undergone liver transplantation pre-
viously. We also excluded participants who had HIV, hepatitis C
virus (HCV), or hepatitis delta virus (HDV) coinfections, or acute
exacerbations of chronic HBV infection. However, we included
participants who did not undergo testing for viral coinfections.
Types of interventions
We included any of the following pharmacological interventions
used either alone or in combination and could be compared with
each other or with placebo or no intervention.
Some of the pharmacological interventions that we considered
were:
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• lamivudine;
• telbivudine;
• clevudine;
• adefovir;
• tenofovir;
• entecavir;
• N-acetyl cysteine;
• ursodeoxycholic acid;
• interferon-alpha;
• pegylated interferon-alpha;
• other interferons;
• thymosin.
The above list of interventions was not an exhaustive list. If we
identified any other pharmacological interventions that we were
not aware of (we included hepatitis B immunoglobulin (HBIG)),
we considered them eligible and included them in the review if
theywere used primarily for the treatment of acuteHBV infection.
Types of outcome measures
We assessed the benefits and harms of available pharmacological
interventions aimed at treating people with acute HBV infection
for the following outcomes.
Primary outcomes
• Short-term mortality (up to one year).
• Progression to chronic HBV infection or to fulminant
hepatitis HBV infection (in trials that included only participants
without fulminant HBV infection).
• Adverse events (within three months of cessation of
treatment). We defined a non-serious adverse event as any
untoward medical occurrence not necessarily having a causal
relationship with the treatment but resulting in a dose reduction
or discontinuation of treatment (any time after commencement
of treatment) (ICH-GCP 1997). We defined a serious adverse
event as any event that would increase mortality; was life
threatening; required hospitalisation; resulted in persistent or
significant disability; was a congenital anomaly/birth defect; or
any important medical event that might have jeopardised the
person or required intervention to prevent it. We planned to use
the definition used by study authors for non-serious adverse
events and serious adverse events:
◦ proportion of participants with serious adverse events;
◦ number of serious adverse events;
◦ proportion of participants with any type of adverse
event;
◦ number of any type of adverse event.
• Health-related quality of life as defined in the included
trials using a validated scale such as EQ-5D or 36-item Short
Form (SF-36) (EuroQol 2014; Ware 2014):
◦ short-term (up to one year);
◦ medium-term (one to five years);
◦ long-term (beyond five years).
We considered short-term quality of life more important than
medium-term or long-term quality of life, although medium-term
or long-term quality of life are also important primary outcomes.
Secondary outcomes
• Mortality:
◦ medium-term mortality (one to five years)
(proportion);
◦ time to death (maximal follow-up).
• Liver transplantation:
◦ proportion of participants with liver transplantation
(for fulminant HBV infection);
◦ time to liver transplantation (maximal follow-up).
• Cirrhosis (maximal follow-up):
◦ proportion of participants with cirrhosis;
◦ time to cirrhosis.
• Decompensated liver disease (maximal follow-up):
◦ proportion of participants with decompensated liver
disease;
◦ time to liver decompensation.
• Proportion of participants with hepatocellular carcinoma
(maximal follow-up).
Potential surrogate outcomes (added post hoc)
We have reported seroconversion which is sometimes used as a
surrogate for progression to chronic HBV infection.
Search methods for identification of studies
Electronic searches
We searched the Cochrane Central Register of Controlled Trials
(CENTRAL), MEDLINE (OvidSP), Embase (OvidSP), and Sci-
ence Citation Index Expanded (Web of Knowledge) (Royle 2003)
from inception to 11 August 2016 for randomised clinical tri-
als comparing two or more of the above interventions (includ-
ing placebo or no intervention) without applying any language
restrictions. We searched for all possible comparisons formed
by the interventions of interest. To identify further ongoing or
completed trials, we also searched the World Health Organiza-
tion International Clinical Trials Registry Platform search por-
tal (www.who.int/ictrp/en/), which encompasses various trial reg-
isters, including ISRCTN and ClinicalTrials.gov on 11 August
2016. Appendix 2 shows the search strategies that we used and the
time spans of the searches.
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Searching other resources
We searched the references of the identified trials and planned to
search existing systematic reviews on acute HBV infection (we did
not find any existing systematic reviews on this topic) to identify
additional trials for inclusion.
Data collection and analysis
Selection of studies
Three review authors (KM, MR, and KG) independently identi-
fied the trials for inclusion by screening the titles and abstracts.
We sought full-text articles for any references that at least one of
the review authors identified for potential inclusion. We selected
trials for inclusion based on the full-text articles. We have listed
the excluded full-text references with reasons for their exclusion
in the Characteristics of excluded studies table. We planned to list
any ongoing trials identified primarily through the search of the
clinical trial registers for further follow-up; however, we did not
find any ongoing trials on the topic. We resolved discrepancies
through discussion.
Data extraction and management
Three review authors (KM,MR, andKG) independently extracted
the following data.
• Outcome data (for each outcome and for each treatment
arm whenever applicable):
◦ number of participants randomised;
◦ number of participants included for the analysis;
◦ number of participants with events for binary
outcomes, mean and standard deviation for continuous
outcomes, number of events for count outcomes, and number of
participants with events and mean follow-up period for time-to-
event outcomes;
◦ definition of outcomes or scale used if appropriate.
• Data on potential confounding variables:
◦ participant characteristics such as age, sex,
comorbidity, proportion of participants with asymptomatic or
mild acute HBV infection versus severe acute HBV infection or
fulminant HBV infection, and proportion of participants with
different HBV genotypes;
◦ details of the intervention and control (including dose,
frequency, and duration);
◦ risk of bias (assessment of risk of bias in included
studies).
• Other data:
◦ year and language of publication;
◦ country in which the participants were recruited;
◦ year(s) in which the trial was conducted;
◦ inclusion and exclusion criteria;
◦ follow-up time points of the outcome.
If available, we planned to obtain the data separately for treatment-
naive, non-responders, and relapsers from the report. If available,
we also planned to obtain the data separately on participants with
asymptomatic or mild acute HBV infection compared to severe
acute HBV infection, or fulminant HBV infection, and partici-
pants with different genotypes. We sought unclear or missing in-
formation by attempting to contact the trial authors. If there was
any doubtwhether trials shared the same participants -- completely
or partially (by identifying common authors and centres) -- we
planned to attempt to contact the trial authors to clarify whether
the trial report was duplicated; however, there were no such trials.
We resolved any differences in opinion through discussion.
Assessment of risk of bias in included studies
We followed the guidance given in the Cochrane Handbook for
Systematic Reviews of Interventions (Higgins 2011), and described
in the Cochrane Hepato-Biliary Module (Gluud 2016), to assess
the risk of bias in included studies. Specifically, we assessed the risk
of bias in included trials for the following domains using the bias
risk domains with definitions below (Schulz 1995; Moher 1998;
Kjaergard 2001; Wood 2008; Savovi 2012a; Savovi 2012b;
Lundh 2017).
Allocation sequence generation
• Low risk of bias: sequence generation was achieved using
computer random number generation or a random number
table. Drawing lots, tossing a coin, shuffling cards, and throwing
dice were adequate if performed by an independent person not
otherwise involved in the trial.
• Unclear risk of bias: the method of sequence generation was
not specified.
• High risk of bias: the sequence generation method was not
random.
Allocation concealment
• Low risk of bias: the participant allocations could not have
been foreseen in advance of, or during, enrolment. Allocation
was controlled by a central and independent randomisation unit.
The allocation sequence was unknown to the investigators (e.g. if
the allocation sequence was hidden in sequentially numbered,
opaque, and sealed envelopes).
• Unclear risk of bias: the method used to conceal the
allocation was not described so that intervention allocations may
have been foreseen in advance of, or during, enrolment.
• High risk of bias: the allocation sequence was likely to be
known to the investigators who assigned the participants.
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Blinding of participants and personnel
• Low risk of bias: any of the following: no blinding or
incomplete blinding, but the review authors judged that the
outcome was not likely to be influenced by lack of blinding; or
blinding of participants and key study personnel ensured, and it
was unlikely that the blinding could have been broken.
• Unclear risk of bias: any of the following: insufficient
information to permit judgement of ’low risk’ or ’high risk’; or
the trial did not address this outcome.
• High risk of bias: any of the following: no blinding or
incomplete blinding, and the outcome was likely to be
influenced by lack of blinding; or blinding of key study
participants and personnel attempted, but likely that the
blinding could have been broken, and the outcome was likely to
be influenced by lack of blinding.
Blinding of outcome assessors
• Low risk of bias: any of the following: no blinding of
outcome assessment, but the review authors judged that the
outcome measurement was not likely to be influenced by lack of
blinding; or blinding of outcome assessment ensured, and
unlikely that the blinding could have been broken.
• Unclear risk of bias: any of the following: insufficient
information to permit judgement of ’low risk’ or ’high risk’; or
the trial did not address this outcome.
• High risk of bias: any of the following: no blinding of
outcome assessment, and the outcome measurement was likely
to be influenced by lack of blinding; or blinding of outcome
assessment, but likely that the blinding could have been broken,
and the outcome measurement was likely to be influenced by
lack of blinding.
Incomplete outcome data
• Low risk of bias: missing data were unlikely to make
treatment effects depart from plausible values. Sufficient
methods, such as multiple imputation, has been employed to
handle missing data.
• Unclear risk of bias: there was insufficient information to
assess whether missing data in combination with the method
used to handle missing data were likely to induce bias on the
results.
• High risk of bias: the results were likely to be biased due to
missing data.
Selective outcome reporting
• Low risk of bias: the trial reported at least short-term
mortality, progression to chronic HBV infection, and treatment-
related adverse events. If the original trial protocol was available,
the outcomes should have been those called for in that protocol.
If the trial protocol was obtained from a trial registry (e.g.
www.clinicaltrials.gov), the outcomes sought should have been
those enumerated in the original protocol if the trial protocol
was registered before or at the time that the trial was begun. If
the trial protocol was registered after the trial was begun, those
outcomes were not considered to be reliable.
• Unclear risk of bias: not all predefined, or clinically relevant
and reasonably expected, outcomes were reported fully, or it was
unclear whether data on these outcomes were recorded or not.
• High risk of bias: one or more predefined or clinically
relevant and reasonably expected outcomes were not reported,
even though data on these outcomes were likely to have been
available and even recorded.
For-profit bias
• Low risk of bias: the trial appeared to be free of industry
sponsorship or other type of for-profit support that may
manipulate the trial design, conductance, or results of the trial.
• Unclear risk of bias: the trial may or may not have been free
of for-profit bias as no information on clinical trial support or
sponsorship was provided.
• High risk of bias: the trial was sponsored by industry or
received other type of for-profit support.
Other bias
• Low risk of bias: the trial appeared to be free of other
components (e.g. inappropriate control or dose or
administration of control) that could put it at risk of bias.
• Unclear risk of bias: the trial may or may not have been free
of other components that could put it at risk of bias.
• High risk of bias: there are other factors in the trial that
could put it at risk of bias (e.g. inappropriate control or dose or
administration of control).
We considered a trial at low risk of bias if we assessed the trial
to be at low risk of bias across all the above domains. Otherwise,
we considered trials at unclear risk of bias or at high risk of bias
regarding one or more of the above domains at high risk of bias.
Measures of treatment effect
For dichotomous variables (e.g. short-term and medium-term
mortality, liver transplantation, progression to chronic HBV, pro-
portion of participants with adverse events, decompensated liver
disease, cirrhosis, or hepatocellular carcinoma), we calculated the
odds ratio (OR) with 95% confidence intervals (CI). For contin-
uous variables (e.g. quality of life reported on the same scale), we
calculated themean difference (MD)with 95%CI.We planned to
use standardised mean difference values with 95% CI for quality
of life if included trials used different scales. For count outcomes
(e.g. number of adverse events), we calculated the rate ratio with
95% CI. For time-to-event data (e.g. mortality at maximal follow-
10Pharmacological interventions for acute hepatitis B infection: an attempted network meta-analysis (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
up or requirement for liver transplantation, time to liver decom-
pensation, and time to cirrhosis), we planned to use the hazard
ratio with 95% CIs. We also calculated Trial Sequential Analysis-
adjusted CI to control random errors (Thorlund 2011; Wetterslev
2017).
Unit of analysis issues
The unit of analysis was people with acute HBV infection accord-
ing to the intervention group to which they were randomly as-
signed.
Cluster randomised clinical trials
We found no cluster randomised clinical trials. However, if we
found such trials, we planned to include these, provided that the
effect estimate adjusted for cluster correlation was available.
Cross-over randomised clinical trials
As expected, we found no cross-over randomised clinical trials.
However, if we had identified any, we planned to only include the
outcomes after the period of first treatment to avoid a potentially
residual effect (the carryover effect) from the treatment adminis-
tered during the first period.
Trials with multiple intervention groups
We collected data for all trial intervention groups that met the
inclusion criteria.
Dealing with missing data
We performed an intention-to-treat analysis whenever possible
(Newell 1992). Otherwise, we used the data that were available
to us (e.g. a trial may have reported only ’per-protocol’ analysis
results). As such per-protocol analyses may be biased, we planned
to conduct best-worst case scenario (good outcome (e.g. no mor-
tality) in intervention group and bad outcome (e.g. mortality) in
control group) and worst-best case scenario (bad outcome (e.g.
mortality) in intervention group and good outcome (e.g. no mor-
tality) in control group) analyses as sensitivity analyses whenever
possible.
For continuous outcomes, we planned to impute the standard de-
viation from P values according to guidance given in the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011). If
the data were likely to be normally distributed, we planned to use
the median for meta-analysis when the mean was not available. If
it was not possible to calculate the standard deviation from the P
value or the CIs, we planned to impute the standard deviation us-
ing the largest standard deviation in other trials for that outcome.
This form of imputation may decrease the weight of the study for
calculation of MDs and may bias the effect estimate to no effect
for calculation of standardised mean differences (Higgins 2011).
Assessment of heterogeneity
We assessed clinical andmethodological heterogeneity by carefully
examining the characteristics and design of included trials. We as-
sessed or planned to assess the presence of clinical heterogeneity by
comparing effect estimates in participants with asymptomatic or
mild acute HBV infection compared to severe acute HBV infec-
tion or fulminant HBV infection, different HBV genotypes, and
the different regimens (e.g. different doses and different durations)
of the pharmacological interventions. Different study designs and
risk of bias may contribute to methodological heterogeneity. We
used the I2 test and Chi2 test for heterogeneity, and overlapping
of CIs to assess heterogeneity.
Assessment of reporting biases
We planned to use visual asymmetry on a funnel plot to explore
reporting bias in the presence of at least 10 trials that could be
included for a direct comparison (Egger 1997;Macaskill 2001). In
the presence of heterogeneity that could be explained by subgroup
analysis, we planned to produce a funnel plot for each subgroup
in the presence of the adequate number of trials. We planned to
use the linear regression approach described by Egger 1997 to
determine the funnel plot asymmetry.
We also considered selective reporting as evidence of reporting
bias.
Data synthesis
We performed the meta-analyses according to the recommenda-
tions of Cochrane (Higgins 2011), using the software package Re-
viewManager 5 (RevMan 2014).We used a random-effects model
(DerSimonian 1986) and a fixed-effect model (DeMets 1987). In
the case of a discrepancy between the two models, we reported
both results; otherwise, we reported only the results from the fixed-
effect model.
Calculation of required information size and Trial Sequential
Analysis
For calculation of the required information size, see Appendix
3. We performed Trial Sequential Analysis to control the risks
of random errors when there were at least two trials included in
the meta-analysis (Wetterslev 2008; Thorlund 2011; TSA 2011;
Wetterslev 2017). We used an alpha error as per guidance of
Jakobsen 2014, power of 90% (beta error of 10%), a relative risk
reduction of 20%, a control group proportion observed in the
trials, and the diversity observed in the meta-analysis.
Subgroup analysis and investigation of heterogeneity
Weplanned to assess the differences in the effect estimates between
the following subgroups.
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• Trials with low risk of bias compared to trials with high risk
of bias.
• Asymptomatic or mild acute HBV infection compared to
severe acute HBV infection or fulminant HBV infection.
• Different HBV genotypes.
• Different regimens (different doses and different durations)
of pharmacological interventions.
Weplanned touse theChi2 test for subgroupdifferences to identify
subgroup differences.
Sensitivity analysis
If a trial reported only per-protocol analysis results, we planned
to re-analyse the results using the best-worst case scenario and
worst-best case scenario analyses as sensitivity analyses whenever
possible.
Presentation of results and GRADE assessments
We reported all the primary outcomes in a ’Summary of findings’
table format for comparisons with at least two trials, downgrading
the quality of evidence for risk of bias, inconsistency, indirectness,
imprecision, and publication bias using GRADE (Guyatt 2011).
One review author (KG) created the ’Summary of findings’ table.
R E S U L T S
Description of studies
Results of the search
We identified 2676 references through electronic searches ofCEN-
TRAL (n = 238), MEDLINE (n = 1786), Embase (n = 310),
Science Citation Index Expanded (n = 322), World Health Or-
ganization International Clinical Trials Registry Platform (n =
10), and ClinicalTrials.gov trials registers (n = 10). After the re-
moval of 446 duplicates we obtained 2230 references. We then
excluded 2215 clearly irrelevant references through screening titles
and reading abstracts. We retrieved 15 references for further assess-
ment. No references were identified through scanning reference
lists of the identified randomised trials. We excluded seven refer-
ences for the reasons listed in Characteristics of excluded studies
table (Gregory 1976; Blum 1977; Botero 1991; Flisiak 2000;
Sharapov 2000; Tillmann 2006; Yu 2010). In total, seven trials
(eight references) met the inclusion criteria (Anonymous 1974;
Tassopoulos 1989; Tassopoulos 1997; Apostolescu 2001; Kumar
2007; Wiegand 2014; Streinu-Cercel 2016). The reference flow is
summarised in the study flow diagram (Figure 1).
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Figure 1. Study flow diagram. HBV: hepatitis B virus; RCT: randomised clinical trial.
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Included studies
The seven trials included 597 participants (Anonymous 1974;
Tassopoulos 1989; Tassopoulos 1997; Apostolescu 2001; Kumar
2007; Wiegand 2014; Streinu-Cercel 2016). In these seven trials,
597 participants were randomised and data on one or more out-
comes were available for 592 participants. One trial was a three-
armed trial which compared lamivudine, entecavir, and no inter-
vention (Streinu-Cercel 2016). The remaining six trials were two-
armed trials (Anonymous 1974; Tassopoulos 1989; Tassopoulos
1997; Apostolescu 2001; Kumar 2007; Wiegand 2014). The de-
tails of intervention, control, and the period of follow-up, and the
risk of bias in the trials arranged according to intervention and
control is summarised in Table 1. One trial (55 participants) com-
pared HBIG versus placebo (Anonymous 1974). Two trials (200
participants) compared interferon versus placebo (Tassopoulos
1989; Tassopoulos 1997). Four trials (316 participants) com-
pared lamivudine versus placebo or no intervention (Apostolescu
2001; Kumar 2007; Wiegand 2014; Streinu-Cercel 2016). One
trial (90 participants) compared lamivudine versus entecavir
(Streinu-Cercel 2016). One trial (131 participants) compared en-
tecavir versus no intervention (Streinu-Cercel 2016). Overall, five
trials used placebo as the ’no intervention’ (Anonymous 1974;
Tassopoulos 1989; Tassopoulos 1997; Kumar 2007; Wiegand
2014); two trials used ’no intervention’ as the ’no intervention’
(Apostolescu 2001; Streinu-Cercel 2016). The mean or median
follow-up period in the trials ranged from three to 12 months in
the six trials that provided this information (Tassopoulos 1989;
Tassopoulos 1997; Apostolescu 2001; Kumar 2007; Wiegand
2014; Streinu-Cercel 2016).
The mean or median age in the five trials that reported this
information ranged from 32 to 41 years (Tassopoulos 1989;
Tassopoulos 1997; Kumar 2007; Wiegand 2014; Streinu-Cercel
2016). The proportion of females in the trials that reported
this information ranged from 14% to 54% (Tassopoulos 1989;
Tassopoulos 1997; Kumar 2007; Wiegand 2014; Streinu-Cercel
2016). One trial included only participants with acute HBV and
hepatic encephalopathy (i.e. participants with fulminant liver fail-
ure; Anonymous 1974); one trial included only participants with
severe acute HBV, but did not state whether it included fulminant
HBV infection (Streinu-Cercel 2016); three trials excluded people
with fulminant HBV infection (Tassopoulos 1989; Tassopoulos
1997; Wiegand 2014); two trials did not report the severity of
acute HBV infection (Apostolescu 2001; Kumar 2007). None of
the trials reported the proportion of participants with different
HBV genotypes.
Source of funding: two trials received financial assistance from
pharmaceutical companies who would benefit from the findings
of the research or one of the authors was employed by a phar-
maceutical company who would benefit from the findings of the
research (Tassopoulos 1989; Tassopoulos 1997); two trials did not
report the source of funding (Apostolescu 2001; Kumar 2007);
three trials were funded by parties without any vested interest in
the results or did not receive any special funding (Anonymous
1974; Wiegand 2014; Streinu-Cercel 2016)..
Excluded studies
We excluded seven references because they were quasi-randomised
studies (two references: Sharapov 2000; Yu 2010), non-ran-
domised studies (two references: Flisiak 2000; Tillmann 2006),
lack of confirmation of HBV infection in all participants (two ref-
erences: Gregory 1976; Blum 1977), or because only four partic-
ipants in the trial had acute HBV infection (three in intervention
group and one in control group) (Botero 1991).
Risk of bias in included studies
The risk of bias in included trials is summarised in Figure 2 and
Figure 3. None of the trials were at low risk of bias and were at
high risk of bias in one or more domains. So, all the trials were at
high risk of bias.
14Pharmacological interventions for acute hepatitis B infection: an attempted network meta-analysis (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
Three trials were at low risk of random sequence generation bias
(Anonymous 1974; Kumar 2007; Streinu-Cercel 2016). The re-
maining trials were at unclear risk of random sequence generation
bias (Tassopoulos 1989; Tassopoulos 1997; Apostolescu 2001;
Wiegand 2014). One trial was at low risk of allocation con-
cealment bias (Anonymous 1974). The remaining trials were at
unclear risk of allocation concealment bias (Tassopoulos 1989;
Tassopoulos 1997; Apostolescu 2001; Kumar 2007; Wiegand
2014; Streinu-Cercel 2016).
Blinding
Two trials were at low risk of bias due to lack of blinding of partic-
ipants, healthcare providers, and outcome assessors (Tassopoulos
1997; Kumar 2007). One trial was at high risk of bias due to lack
of blinding of participants, healthcare providers, and outcome as-
sessors (Streinu-Cercel 2016). The remaining trials were at un-
clear risk of bias due to lack of blinding of participants, healthcare
providers, and outcome assessors (Anonymous 1974; Tassopoulos
1989; Apostolescu 2001; Wiegand 2014).
Incomplete outcome data
Three trialswere at low risk of bias due to incomplete outcomedata
(Tassopoulos 1997; Kumar 2007; Streinu-Cercel 2016). One trial
was at high risk of bias due to incomplete outcome data (Wiegand
2014). The remaining trials were at unclear risk of bias due to
incomplete outcome data (Anonymous 1974; Tassopoulos 1989;
Apostolescu 2001).
Selective reporting
None of the trials had a published protocol. Two trials reported
mortality, adverse events, and progression to chronic HBV, and
were at low risk of reporting bias (Kumar 2007; Streinu-Cercel
2016). The remaining trials did not report these outcomes, which
can be reasonably expected to be measured in trials in this
field (Anonymous 1974; Tassopoulos 1989; Tassopoulos 1997;
Apostolescu 2001; Wiegand 2014). So, these trials were at high
risk of selecting outcome reporting.
Other potential sources of bias
Three trials were at low risk of vested interest bias (Anonymous
1974; Wiegand 2014; Streinu-Cercel 2016); two trials were at
high risk of vested interest bias (Tassopoulos 1989; Tassopoulos
1997); the remaining trials were at unclear risk of vested interest
bias (Apostolescu 2001; Kumar 2007).
All the trials were at low risk of other bias.
Effects of interventions
See: Summary of findings for themain comparisonLamivudine
versus no intervention for acute hepatitis B virus infection;
Summary of findings 2 Interferon versus no intervention for
acute hepatitis B virus infection
Short-term mortality (up to one year)
Three trials (326 participants) reported short-term mortality
(Anonymous 1974; Kumar 2007; Streinu-Cercel 2016). There
was no evidence of difference in short-term mortality in any of
the comparisons (Analysis 1.1).
• HBIG (19/27 (70.4%)) versus placebo (19/28 (67.9%))
(OR 1.13, 95% CI 0.36 to 3.54; participants = 55; 1 trial).
• Lamivudine (adjusted proportion: 4.3%) versus placebo or
no intervention (5/150 (3.3%)) (OR 1.29, 95% CI 0.33 to 4.99;
participants = 250; 2 trials).
• Lamivudine (4/69 (5.8%)) versus entecavir (1/21 (4.8%))
(OR 1.23, 95% CI 0.13 to 11.65; participants = 90; 1 trial).
• Entecavir (1/21 (4.8%)) versus no intervention (5/110
(4.5%)) (OR 1.05, 95% CI 0.12 to 9.47; participants = 131; 1
trial).
Only one comparison had more than one trial (lamivudine versus
placebo or no intervention). Even in this comparison, only one
trial contributed to the analysis (Streinu-Cercel 2016), as there
were no events in either group in the other trial (Kumar 2007).
Therefore, heterogeneity was not assessed.
Progression to chronic hepatitis B virus infection or
to fulminant hepatitis B virus infection
Three trials (306 participants) reported proportion of people who
continued to haveHBsAg in serum (Kumar 2007;Wiegand 2014;
Streinu-Cercel 2016). The proportion of people who developed
progression to chronic HBV infection was higher in the lamivu-
dine group (adjusted proportion: 58.4%) versus the placebo or
no intervention group (69/167 (41.3%)) (OR 1.99, 95% CI 1.05
to 3.77; participants = 285; 3 trials; I2 = 0%) and in the lamivu-
dine group (53/69 (76.8%)) versus the entecavir group (10/21
(47.6%)) (OR 3.64, 95% CI 1.31 to 10.13; participants = 90; 1
trial). There was no evidence of difference in the proportion of
people who progressed to chronic HBV infection between the en-
tecavir group (10/21 (47.6%)) versus the no intervention group
(67/110 (60.9%)) (OR 0.58, 95% CI 0.23 to 1.49; participants
= 131; 1 trial) (Analysis 1.2).
There was no evidence of heterogeneity in the only comparison
with more than one trial (lamivudine versus placebo or no in-
tervention: I2 = 0%). None of the trials reported progression to
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fulminant hepatitis. Authors also reported seroconversion which
was variably defined in the different trials (see ’Seroconversion
(surrogate outcome)’ below). As this is an unvalidated surrogate
outcome, we presented this information last and did not arrive at
conclusions based on this surrogate outcome.
Adverse events
Three trials (371 participants) reported serious adverse events
(Tassopoulos 1989; Kumar 2007; Streinu-Cercel 2016). There
were no serious adverse events in any of the groups (Analysis 1.3).
Three trials (235 participants) reported proportion of people
with any adverse events (Tassopoulos 1989; Tassopoulos 1997;
Wiegand 2014). The proportion of people with adverse events
was higher in the interferon group (adjusted proportion: 99.2%)
versus the placebo group (18/66 (27.3%)) (OR 348.16, 95% CI
45.39 to 2670.26; participants = 200; 2 trials; low quality evi-
dence: downgraded by one level for risk of bias in the studies and
one more level for small sample size) (Analysis 1.4). There was no
evidence of heterogeneity (I2 = 0%; Chi2 test for heterogeneity
P = 1.00; good overlap of CIs). There was no evidence of dif-
ference in the proportion of people with adverse events between
the lamivudine group (13/18 (72.2%)) versus the placebo or no
intervention (11/17 (64.7%)) (OR 1.42, 95% CI 0.34 to 5.94;
participants = 35; 1 trial) or the number of adverse events between
the lamivudine group (38/18 (211.1 events per 100 participants))
versus the no intervention group (21/17 (123.5 events per 100
participants)) (rate ratio 1.72, 95% CI 1.01 to 2.91; participants
= 35; 1 trial) (Analysis 1.5).
Health-related quality of life
One trial (100 participants) reported health-related quality of life
at one week (Tassopoulos 1997). The scale used to report the
health-related quality of life was not stated. Neither was informa-
tion on whether higher score meant better or worse available. The
mean score in the placebo group was 42.7 units. The mean score
in the interferon group was 5.4 units higher. There was no infor-
mation to calculate the 95% CIs or P value (Analysis 1.6). None
of the trials reported quality of life beyond one week.
Mortality (beyond one year)
None of the trials reported mortality beyond one year.
Liver transplantation
None of the trials reported the proportion of people who required
liver transplantation.
Cirrhosis
None of the trials reported the proportionof peoplewhodeveloped
cirrhosis.
Decompensated liver disease
None of the trials reported the proportionof peoplewhodeveloped
decompensated liver disease.
Hepatocellular carcinoma
None of the trials reported the proportionof peoplewhodeveloped
hepatocellular carcinoma.
Seroconversion (surrogate outcome)
Five trials (437 participants) reported proportion of people who
developed seroconversion (Tassopoulos 1997; Apostolescu 2001;
Kumar 2007; Wiegand 2014; Streinu-Cercel 2016). The defini-
tion of seroconversion in the four trials that reported this infor-
mation were: clearance of HBV DNA (Tassopoulos 1997), hep-
atitis B surface antibody at 12 months (Kumar 2007), hepatitis
B surface antibody at 24 weeks (Streinu-Cercel 2016), and hep-
atitis B surface antibody greater than 10 U/L (Wiegand 2014).
The seroconversion proportions in the different comparisons were
(Analysis 1.8):
• interferon (65/67 (97.0%)) versus placebo (33/33
(100.0%)) (OR 0.39, 95% CI 0.02 to 8.38; participants = 100;
1 trial);
• lamivudine (proportion: varied between 10.1% and 77.8%)
versus placebo or no intervention (proportion varied between
22.7% and 85%) (OR varied between 0.27 and 2.63 (meta-
analysis inappropriate because of variable definitions used for
seroconversion and poor overlap of CI between effect estimates
between trials); participants = 316; 4 trials);
• lamivudine (7/69 (10.1%)) versus entecavir (9/21 (42.9%))
(OR 0.15, 95% CI 0.05 to 0.48; participants = 90; 1 trial);
• entecavir (9/21 (42.9%)) versus no intervention (25/110
(22.7%)) (OR 2.55, 95% CI 0.96 to 6.74; participants = 131; 1
trial).
Of the five trials that reported the proportion of people who
developed seroconversion, two trials (135 participants) reported
the time taken to achieve seroconversion (Tassopoulos 1997;
Wiegand 2014). Of these, only one reported the standard devia-
tion (Tassopoulos 1997). There was no evidence of difference in
the time taken to achieve seroconversion between interferon and
placebo (MD -0.10 weeks, 95% CI -2.02 to 1.82; participants =
100; 1 trial) or between lamivudine and placebo or no interven-
tion (MD 1.00 weeks, P = 0.519 (no details to calculate 95% CI);
participants = 35; 1 trial) (Analysis 1.8; Analysis 1.9).
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Subgroup analysis and sensitivity analysis
We did not perform any of the subgroup analyses because none of
the trials were at low risk of bias, the trials did not report the data
for different genotypes separately, and because there were too few
trials to perform a meaningful subgroup analysis based on severity
of hepatitis B or dosage.Only one trial reported postrandomisation
dropouts but did not report the group to which the participants
belonged. Therefore, we did not perform a sensitivity analysis.
Since we did not impute mean or standard deviations, we did not
perform a sensitivity analysis excluding trials in which mean or
standard deviation were imputed.
Reporting bias
We did not explore reporting bias using funnel plot because of few
trials included in the review.
Trial Sequential Analysis
We performed Trial Sequential Analysis for comparisons with two
ormore trials only (progression to chronicHBV infection: lamivu-
dine versus placebo or no intervention and adverse events (pro-
portion): interferon versus placebo). As shown in Figure 4, the
accrued sample size was only a small fraction of the diversity-ad-
justed required information size (DARIS). The Z-curve did not
cross trial sequential monitoring boundaries indicating that there
was a high risk of random errors in these outcomes.
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Figure 4. Trial sequential analysis of progression to chronic hepatitis B virus infection (lamivudine versus
placebo or no treatment) and adverse events (proportion) (interferon versus placebo): Using the control
group proportion observed in the trials (Pc = 41.3% and 34.9% respectively), alpha error of 2%, beta error of
90%, relative risk reduction (RRR) of 20%, and diversity observed in the analysis (0%), the accrued sample sizes
(285 and 200 respectively) were only small proportions of the diversity-adjusted required information sizes
(DARIS) (progression to chronic hepatitis B = 1783; adverse events (proportion) = 2303). While the Z-curve
(blue lines) crossed the conventional boundary of P = 0.05 (dotted green lines) favouring placebo or no
treatment, it did not cross any of the trial sequential monitoring boundaries (dotted red lines). There was a
high risk of random errors.
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The Trial Sequential Analysis adjusted CIs were as follows.
• Progression to chronic HBV infection: lamivudine versus
no intervention: 1.99 (95% CI 0.15 to 27.06).
• Adverse events (proportion): interferon versus placebo:
348.16 (95% CI 0.09 to 1,422,918.89).
Quality of evidence
The overall quality of evidence was very low for all outcomes unless
indicated. The reason for downgrading was risk of bias in the trials
(one level), small sample size (one level), and wide CIs (one level)
(Summary of findings for the main comparison).
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Interferon versus no intervention for acute hepatitis B virus infection
Patient or population: people with acute HBV infect ion
Settings: secondary or tert iary care
Intervention: interferon
Control: no intervent ion
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(trials)
Quality of the evidence
(GRADE)
Assumed risk Corresponding risk
No intervention Interferon
Short- term mortality None of the trials reported this information.
Progression to chronic HBV
infection
None of the trials reported this information.
Progression to fulminant
HBV infection
None of the trials reported this information.
Serious adverse events There were no serious adverse events in either group. 100
(1 trial)
⊕©©©
Very low1,2,3
Adverse events (propor-
tion) (4 to 6 months)
273 per 1000 992 per 1000
(945 to 999)
OR 348.16
(45.39 to 2670.26)
200
(2 trials)
⊕⊕©©
Low1,2
Adverse events (number of
events)
None of the trials reported this information.
Health- related quality of
life (1 week)
The scale used to report the health-related quality of lif e was not stated. Neither was
information on whether higher score meant better or worse available. The mean score
in the placebo group was 42.7 units. The mean score in the interferon group was 5.4
units higher. There was no information to calculate the 95% conf idence intervals or P
value
100
(1 trial)
⊕©©©
Very low1,2,3
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* The basis for the assumed risk is the mean control group risk in the control group across studies. The corresponding risk (and its 95% conf idence interval) is based on the
assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
CI: conf idence interval; HBV: hepat it is B virus; OR: odds rat io.
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1 The risk of bias in the trial(s) was high (downgraded by 1 level for risk of bias).
2 The sample size was small (downgraded by 1 level for imprecision).
3 The conf idence intervals were wide (downgraded by 1 level for imprecision).
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D I S C U S S I O N
Summary of main results
A total of 597 participants in seven trials were included in this re-
view. A total of 592 participants in these seven trials contributed to
one or more outcomes of this review. A total of five interventions
(four active interventions and one inactive intervention) were eval-
uated in the seven trials included in this review. This included in-
terferon, HBIG, lamivudine, entecavir, and inactive intervention
(placebo or no intervention).
Overall, mortality at three months to one year following inter-
vention in people with acute HBV infection was low (10/271
(3.7%)) (Kumar 2007; Streinu-Cercel 2016), except in the one
trial reported in 1970s, which included only people with fulmi-
nant HBV infection (Anonymous 1974). Mortality in this trial
was 69.1% (38/55) (Anonymous 1974). There was no evidence of
differences in mortality between different interventions regardless
of the severity of HBV infection. However, the sample size was
very low to detect differences in mortality. Three trials reported
the proportion of people who progressed to chronic HBV infec-
tion (defined as persistence of HBsAg after six months). None of
the interventions resulted in reduction in the proportion of people
who progressed to chronic HBV infection compared to placebo
or no intervention. None of the trials reported progression to ful-
minant HBV infection either. None of the participants developed
serious adverse events in the three trials that reported this infor-
mation (Tassopoulos 1989; Kumar 2007; Streinu-Cercel 2016).
The proportion of people who developed adverse events (such as
influenza-like symptoms and vomiting), was more in the inter-
feron group than the placebo group. However, the trial sequen-
tial monitoring boundaries were not crossed, suggesting that there
may be random errors. There was no evidence of a difference in
proportion of people who developed adverse events or the number
of adverse events between lamivudine and placebo or no interven-
tion. Although one trial reported quality of life at one week, the
information was not sufficient to understand whether there was
a difference in quality of life between the two interventions com-
pared in this trial (interferon versus placebo) (Tassopoulos 1997).
None of the trials reported the proportion of people who died
during medium or long term (more than one year’ follow-up);
required liver transplantation; or developed cirrhosis, decompen-
sated liver disease, or developed hepatocellular carcinoma.
The trials reported seroconversion as a surrogate outcome for pro-
gression to chronic HBV infection. The definition used in the tri-
als was variable, reflecting the problem with using lack of serocon-
version as a surrogate marker for chronic HBV infection. In any
case, the only comparison where there was evidence for difference
was lamivudine versus entecavir: seroconversion was lower in peo-
ple who received lamivudine compared with those who received
entecavir. There was no evidence for differences in the time taken
for seroconversion in the trials that reported this information.
Overall completeness and applicability of
evidence
Overall, it appears that none of the interventions are beneficial for
people with acute HBV infection.
Considering that lamivudine or interferon do not offer any ben-
efit but have the potential to cause harm, it may be appropriate
to test entecavir or other similar antiviral interventions such as
tenofovir. We have included all the major interventions used for
treating acute HBV infection that have been compared in ran-
domised clinical trials in this review. The severity of acuteHBV in-
fection was variable across trials. In particular, only one trial clearly
indicated inclusion of fulminant HBV infection (Anonymous
1974). Three trials clearly excluded fulminant HBV infection
(Tassopoulos 1989; Tassopoulos 1997; Wiegand 2014). It was
unclear whether any participants with fulminant HBV infection
were included in the remaining trials (Apostolescu 2001; Kumar
2007; Streinu-Cercel 2016). Considering that the main interven-
tions that are currently recommended for treatment of acute HBV
infection are antiviral drugs (Tillmann 2012) (and there was no
comparison of antiviral interventions versus no intervention in
people with fulminant HBV infection), the findings of this review
are applicable only to people with acute HBV without fulminant
liver failure. The findings are also applicable only in adults with
acute HBV infection, as none of the trials appeared to include
children. The findings are also applicable only in people who have
not undergone liver transplantation and those who do not have
other coexisting viral diseases, since we did not consider trials con-
ducted in these populations.
Quality of the evidence
The overall quality of evidence was low to very low for all the
outcomes. All the trials were at high risk of bias for at least one of
the domains as shown in Figure 2 and Figure 3. The sample size
was small for all the comparisons. There were also wide 95% CIs
(the CIs overlapped 20% increase or decrease and minimal clini-
cal important difference) for many of the comparisons. Moreover,
when we calculated Trial Sequential analysis-adjusted CI, the in-
consistency exploded. There was insufficient information to assess
whether the diagnostic criteria for acute HBV and the severity of
acute hepatitis HBVwere similar across trials. In general, there was
no evidence of statistical heterogeneity in most comparisons with
the exception of the seroconversion in the comparison lamivudine
versus placebo or no intervention, where there was moderate het-
erogeneity.
Potential biases in the review process
We followed the guidance of Cochrane Handbook for Systematic
Reviews of Interventions with two review authors independently
selecting studies and extracting data. We performed a thorough
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search of literature. However, the search period included the pre-
mandatory trial registration era and it is likely that some trials on
interventions that were not effective or were harmful were not re-
ported at all.
We only included randomised clinical trials which are known to
focus mostly on benefits and do not collect and report harms in
a detailed manner. According to our choice of studies (i.e. only
randomised clinical trials), we might have missed a large number
of studies that address reporting of harms. Accordingly, this review
is biased towards benefits ignoring harms. We did not search for
interventions and trials registered at regulatory authorities (e.g.
US Food and Drug Administration; European Medicines Agency,
etc.). This may have overlooked trials and as such trials usually
are unpublished, the lack of inclusion of such trials may make our
comparisons look more advantageous than they really are. How-
ever, this is of academic interest only because there is no evidence
of benefit of any treatment in people with acute HBV infection
(i.e. there is no reason to suggest that any of the interventions
should be used in routine clinical practice regardless of the adverse
event profile of the intervention).
We planned to perform a network meta-analysis. However, it was
not possible to assess whether the potential effect modifiers were
similar across different comparisons. Performing a network meta-
analysis in this scenario can be misleading. So we did not perform
the network meta-analysis, and assessed the comparative bene-
fits and harms of different interventions using standard Cochrane
methodology.
Agreements and disagreements with other
studies or reviews
This is the first systematic review on the topic.Our review does not
support the recommendations of EASL or the AASLD (AASLD
2009; EASL 2012). This is probably because we have based our
conclusions on randomised clinical trials. Information from non-
randomised studies is likely to provide biased effect estimates, since
the people who receive antiviral drugs are likely to differ signifi-
cantly from those who do not receive antiviral drugs.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Low or very low quality evidence suggests that progression to
chronic hepatitis B virus (HBV) infection was higher in people
receiving lamivudine compared with placebo, no intervention, or
entecavir. Low quality evidence suggests that interferon may in-
crease the proportion of people who develop adverse events after
treatment for acute HBV infection. Thus, there is a likelihood
that reality is worse. Based on very low quality evidence, there is
currently no evidence of benefit of any intervention in acute HBV
infection. There is significant uncertainty in this issue and further
randomised clinical trials are required.
Implications for research
Researchers should use clinical outcomes for research on this topic.
The trials should include placebo as one of the treatment arms since
there has been no evidence from randomised clinical trials that any
of the interventions are effective in improving clinical outcomes.
Considering that lamivudine or interferon do not offer any benefit
but have the potential to cause harm, it may be appropriate to test
entecavir or other similar antiviral interventions such as tenofovir
against placebo. The participants should be followed up for at
least one year and progression to chronic HBV infection should
be one of the primary outcomes in such trials. In trials of people
with acute fulminant failure, mortality or requirement for liver
transplantation are suitable primary outcomes. The trials should be
designed and reported using guidance from the SPIRIT statement
(Standard Protocol Items: Recommendations for Interventional
Trials; Chan 2013) and the CONSORT statement (Schulz 2010).
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Anonymous 1974
Methods Randomised clinical trial.
Participants Country: US.
Number randomised: 55.
Postrandomisation dropouts: not stated.
Revised sample size: 55.
Mean age: not stated.
Females: not stated.
Inclusion criteria
• Acute illness clinically compatible with viral hepatitis.
• Progression within 6 weeks of onset of first symptoms from stage II to stage IV
encephalopathy.
• Prothrombin time ≤ 20%.
• Positive test for hepatitis B antigen.
Interventions Participants were randomly assigned to 2 groups.
Group 1: HBIG 8 mL for 6 months and then 32 mL (n = 27).
Group 2: placebo (n = 28).
Outcomes Mortality.
Notes Follow-up period: not stated.
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Accession were stratified by a centralised computer
program for stage of encephalopathy…”
Allocation concealment (selection bias) Low risk Quote: “Accession were stratified by a centralised computer
program for stage of encephalopathy…”
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: the placebo was indistinguishable from the
HBIG treatment, but they did not say whether participants
or clinicians (or both) were blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: the placebo was indistinguishable from the
HBIG treatment, but they did not say whether outcome
assessors were blinded
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: information not available.
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Anonymous 1974 (Continued)
Selective reporting (reporting bias) High risk Comment: neither adverse events nor progression to
chronic HBV
For-profit bias Low risk Comment: study funded by the National Heart and Lung
Institute
Other bias Low risk Comment: no risk of other bias.
Apostolescu 2001
Methods Randomised clinical trial.
Participants Country: Romania.
Number randomised: 31.
Postrandomisation dropouts: not stated.
Revised sample size: 31.
Mean age: not stated.
Females: not stated.
Inclusion criteria
• Acute viral hepatitis with HBV.
Interventions Participants were randomly assigned to 2 groups.
Group 1: lamivudine 100 mg once daily for 3 months (n = 15).
Group 2: no intervention (n = 16).
Outcomes Seroconversion.
Notes Follow-up period: minimum 3 months.
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: information not available.
Allocation concealment (selection bias) Unclear risk Comment: information not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: although authors stated double blind, further
details (e.g. whether placebo used) not reported
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: although authors stated double blind, further
details (e.g. whether placebo used) not reported
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: information not available.
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Apostolescu 2001 (Continued)
Selective reporting (reporting bias) High risk Comment: mortality, adverse events, and progression to
chronic HBV not reported
For-profit bias Unclear risk Comment: information not available.
Other bias Low risk Comment: no risk of other bias.
Kumar 2007
Methods Randomised clinical trial.
Participants Country: India.
Number randomised: 71.
Postrandomisation dropouts: 0 (0%).
Revised sample size: 71.
Mean age: 37 years.
Females: 19 (26.8%).
Inclusion criteria
• Acute HBV: recent onset of acute illness including prodromal symptoms,
jaundice, and other typical symptoms.
• Laboratory test results that supported the diagnosis of acute hepatitis (serum
alanine transaminase and serum bilirubin levels > 2.5 times the upper limit and a
positive immunoglobulin M anti-HBc test.
Exclusion criteria
• Coinfection.
• History of hepatotoxic drug intake.
• Alcohol use > 20 g/day.
• Evidence of past chronic liver disease at presentation or during follow-up.
• Serum bilirubin < 5 mg/dL at presentation.
Interventions Participants were randomly assigned to 2 groups.
Group 1: lamivudine 100 mg once daily for 3 months (n = 31).
Group 2: placebo (n = 40).
Outcomes Mortality, adverse events, progression to chronic HBV infection, and seroconversion
Notes Follow-up period: minimum 12 months
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Randomization was done with a random number
table.”
Allocation concealment (selection bias) Unclear risk Comment: information not available.
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Kumar 2007 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Comment: investigators and participants blinded to ran-
domisation arm
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Comment: investigators and participants blinded to ran-
domisation arm
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: were no postrandomisation dropouts.
Selective reporting (reporting bias) Low risk Comment: mortality, adverse events, and progression to
chronic HBV reported
For-profit bias Unclear risk Comment: source of funding not reported.
Other bias Low risk Comment: was no risk of other bias.
Streinu-Cercel 2016
Methods Randomised clinical trial.
Participants Country: Romania.
Number randomised: 200.
Postrandomisation dropouts: 0 (0%).
Revised sample size: 200.
Mean age: 36 years.
Females: 107 (53.5%).
Inclusion criteria
• People with severe acute HBV infection.
• Previous negative screening for HBsAg within previous 6 months.
Exclusion criteria
• Viral infections such as Epstein-Barr virus, cytomegalovirus, or HIV.
• Other causes of hepatitis including viral and non-viral causes.
• Prior exposure to study drugs.
• Other chronic liver diseases.
• Obstructive or haemolytic malignant jaundice.
• Systemic causes of prolonged prothrombin time.
• Intravenous drug use.
• History of drug hypersensitivity.
• Alcohol or substance abuse or prior therapy that would make the subject
unsuitable for treatment.
Interventions Participants were randomly assigned to 3 groups.
Group1: lamivudine 100mgonce daily oral until seroconversion, development of serious
adverse events, or for maximum of 24 weeks (n = 69).
Group 2: entecavir 0.5 mg once daily oral until seroconversion, development of serious
adverse events, or for maximum of 24 weeks (n = 21)
Group 3: no intervention (n = 105).
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Streinu-Cercel 2016 (Continued)
Outcomes Mortality, progression to chronic HBV infection, and seroconversion
Notes Follow-up period: minimum 11 months.
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “A computer-generated list of random numbers was
used.”
Allocation concealment (selection bias) Unclear risk Comment: information not available.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote: “Thiswas a prospective, open-label study conducted
in Romania… Given the different formulation and ap-
pearance of the administered drugs (lamivudine comes as
oval-shaped, white tablets and entecavir as triangular, blue
tablets) and the individualised nature of the usual care ad-
ministered in the control group, masking could not be per-
formed and patients and physicians were aware of the allo-
cated groups.”
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Quote: “Thiswas a prospective, open-label study conducted
in Romania… Given the different formulation and ap-
pearance of the administered drugs (lamivudine comes as
oval-shaped, white tablets and entecavir as triangular, blue
tablets) and the individualised nature of the usual care ad-
ministered in the control group, masking could not be per-
formed and patients and physicians were aware of the allo-
cated groups.”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: intention-to-treat analysis performed including
all randomised participants
Selective reporting (reporting bias) High risk Comment: mortality and adverse events reported; however,
progression to chronic HBV not reported
For-profit bias Low risk Quote: “Financial support and sponsorship: nil.”
Other bias Low risk Comment: no risk of other bias.
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Tassopoulos 1989
Methods Randomised clinical trial.
Participants Country: Greece.
Number randomised: 100.
Postrandomisation dropouts: not stated.
Revised sample size: 100.
Mean age: 33 years.
Females: 39 (39%).
Inclusion criteria
• Acute benign hepatitis.
Interventions Participants were randomly assigned to 2 groups.
Group 1: interferon-alpha 3 MU or 10 MU 3 times weekly for 3 weeks (n = 67).
Group 2: placebo (n = 33).
Outcomes Adverse events.
Notes Follow-up period: minimum 5 months.
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: information not available.
Allocation concealment (selection bias) Unclear risk Comment: information not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: although a placebo was used in this double-
blind trial, it was not clear whether placebo was identical
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: although a placebo was used in this double-
blind trial, it was not clear whether placebo was identical
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: information not available.
Selective reporting (reporting bias) High risk Comment: neither mortality nor progression to chronic
HBV reported
For-profit bias High risk Comment: 1 of the coauthors was an employee of a phar-
maceutical company
Other bias Low risk Comment: no risk of other bias.
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Tassopoulos 1997
Methods Randomised clinical trial.
Participants Country: Greece.
Number randomised: 100.
Postrandomisation dropouts: 0 (0%).
Revised sample size: 100.
Mean age: 32 years.
Females: 39 (39%).
Inclusion criteria
• Symptoms and signs compatible with the occurrence of acute HBV for < 1 month.
Exclusion criteria
• Aged > 65 years.
• Fulminant course.
• Therapy with steroids.
• Immunosuppressive drugs or parenteral antiviral drugs.
• Pregnancy.
• HIV positive.
• Serious medical illness.
• History of chronic liver disease.
• Alcoholism or metabolic liver disease.
• Exposure within the past 2 months to hepatotoxic drugs.
• Parenteral drug use.
Interventions Participants were randomly assigned to 2 groups.
Group 1: recombinant interferon alpha2b 3 MU or 10 MU 3 times weekly subcuta-
neously for 3 weeks (n = 67).
Group 2: placebo (n = 33).
Outcomes Adverse events, quality of life, seroconversion, and time to seroconversion
Notes Follow-up period: minimum 5 months.
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “patients were randomly assigned to one of the three
treatment options using the randomization sequences pre-
pared by Schering-Plough Corporation, the sponsor of the
study.”
Comment: further details of random sequence generation
not available
Allocation concealment (selection bias) Unclear risk Quote: “patients were randomly assigned to one of the three
treatment options using the randomization sequences pre-
pared by Schering-Plough Corporation, the sponsor of the
study.”
Comment: further details of allocation concealment not
available
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Tassopoulos 1997 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “neither the patients nor the investigators knew
which drug the patients received.”
Comment: placebo used to achieve blinding.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “neither the patients nor the investigators knew
which drug the patients received.”
Comment: placebo used to achieve blinding.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: all participants were included for the analysis of
most outcomes
Selective reporting (reporting bias) High risk Comment: neither mortality nor progression to chronic
HBV reported
For-profit bias High risk Comment: trial funded by a party with vested interest in
the results (funded by Schering-Plough)
Other bias Low risk Comment: no risk of other bias.
Wiegand 2014
Methods Randomised clinical trial.
Participants Country: Germany.
Number randomised: 40.
Postrandomisation dropouts: 5 (12.5%).
Revised sample size: 35.
Mean age: 41 years.
Females: 5 (14.3%).
Inclusion criteria
• Severe non-fulminant acute HBV infection.
• Aged ≥ 18 years.
Exclusion criteria
• Other liver diseases.
• Ongoing drug abuse.
• Organ transplantation.
• Any immunosuppressive therapy or chemotherapy.
• Renal impairment.
• Pregnancy or lactation.
• Predicted low compliance.
Interventions Participants were randomly assigned to 2 groups.
Group 1: lamivudine 100 mg once daily for 4 weeks after disappearance of HBsAg in
serum or maximum of 24 weeks (n = 18).
Group 2: placebo (n = 17).
Outcomes Adverse events, seroconversion, and time to seroconversion.
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Wiegand 2014 (Continued)
Notes Follow-up period: not stated.
Reasons for postrandomisation dropouts: violated inclusion criteria, withdrawn consent,
or worsening of disease to treatment
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: information not available.
Allocation concealment (selection bias) Unclear risk Comment: information not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: although a placebo was used in this double-
blind trial, it was not clear whether placebo was identical
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: although a placebo was used in this double-
blind trial, it was not clear whether placebo was identical
Incomplete outcome data (attrition bias)
All outcomes
High risk Comment: there were postrandomisation dropouts.
Selective reporting (reporting bias) High risk Comment: neither mortality nor progression to chronic
HBV reported
For-profit bias Low risk Quote: “the study was not supported by any manufacturer
of lamivudine.”
Other bias Low risk Comment: no risk of other bias.
anti-HBc: antibody to hepatitis B core antigen; HBIG: hepatitis B immunoglobulin; HBsAg: hepatitis B surface antigen; HBV: hepatitis
B virus.
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Blum 1977 Hepatitis B virus infection not confirmed in all participants
Botero 1991 Not participants with hepatitis B virus infection.
Flisiak 2000 Not a randomised clinical trial.
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(Continued)
Gregory 1976 Hepatitis B virus infection not confirmed in all participants
Sharapov 2000 Quasi-randomised study (allocation based on alphabet of participant’s name)
Tillmann 2006 Not a randomised clinical trial.
Yu 2010 Quasi-randomised study (allocation based on admission order)
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D A T A A N D A N A L Y S E S
Comparison 1. Pharmacological treatments for acute hepatitis B virus infection
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mortality 3 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
1.1 Hepatitis B
immunoglobulin (HBIG)
versus placebo
1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.2 Lamivudine versus
placebo or no intervention
2 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.3 Lamivudine versus
entecavir
1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.4 Entecavir versus no
intervention
1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2 Chronic hepatitis B virus
infection
3 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
2.1 Lamivudine versus
placebo or no intervention
3 285 Odds Ratio (M-H, Fixed, 95% CI) 1.99 [1.05, 3.77]
2.2 Lamivudine versus
entecavir
1 90 Odds Ratio (M-H, Fixed, 95% CI) 3.64 [1.31, 10.13]
2.3 Entecavir versus no
intervention
1 131 Odds Ratio (M-H, Fixed, 95% CI) 0.58 [0.23, 1.49]
3 Serious adverse events Other data No numeric data
3.1 Interferon versus placebo Other data No numeric data
3.2 Lamivudine versus
placebo or no intervention
Other data No numeric data
3.3 Lamivudine versus
entecavir
Other data No numeric data
3.4 Entecavir versus no
intervention
Other data No numeric data
4 Adverse events proportion 3 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
4.1 Interferon versus placebo 2 200 Odds Ratio (M-H, Fixed, 95% CI) 348.16 [45.39,
2670.26]
4.2 Lamivudine versus
placebo or no intervention
1 35 Odds Ratio (M-H, Fixed, 95% CI) 1.42 [0.34, 5.94]
5 Adverse events number 1 Rate Ratio (Fixed, 95% CI) Totals not selected
5.1 Lamivudine versus
placebo or no intervention
1 Rate Ratio (Fixed, 95% CI) 0.0 [0.0, 0.0]
6 Health-related quality of life Other data No numeric data
6.1 Interferon versus placebo Other data No numeric data
7 Seroconversion 5 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
7.1 Interferon versus placebo 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
7.2 Lamivudine versus
placebo or no intervention
4 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
7.3 Lamivudine versus
entecavir
1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
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7.4 Entecavir versus no
intervention
1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
8 Time to seroconversion 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
8.1 Interferon versus placebo 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
9 Time to seroconversion [weeks] Other data No numeric data
9.1 Lamivudine versus
placebo or no intervention
Other data No numeric data
A D D I T I O N A L T A B L E S
Table 1. Characteristics of included studies arranged according to comparison
Study
name
Inter-
vention
Con-
trol
Fol-
low-up
period
(months)
Se-
quence
genera-
tion
Alloca-
tion
con-
ceal-
ment
Blind-
ing of
partic-
ipants
and
health-
care
providers
Blind-
ing
of out-
come
asses-
sors
Incom-
plete
out-
come
data
Selec-
tive
out-
come
report-
ing
Source
of
fund-
ing
Other
bias
Over-
all risk
of bias
Anony-
mous
1974
Hep-
atitis
B Im-
munoglob-
ulin
Placebo Not
stated
Low Low Unclear Unclear Unclear High Low Low High
Tas-
sopou-
los
1989
Inter-
feron
Placebo Min 5 Unclear Unclear Unclear Unclear Unclear High High Low High
Tas-
sopou-
los
1997
Inter-
feron
Placebo Min 5 Unclear Unclear Low Low Low High High Low High
Aposto-
lescu
2001
Lamivu-
dine
No in-
terven-
tion
Min 3 Unclear Unclear Unclear Unclear Unclear High Unclear Low High
Kumar
2007 Lamivu-
dine
Placebo Min 12 Low Unclear Low Low Low Low Unclear Low Unclear
Wie-
gand
2014
Lamivu-
dine
Placebo Not
stated
Unclear Unclear Unclear Unclear High High Low Low High
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Table 1. Characteristics of included studies arranged according to comparison (Continued)
Streinu-
Cercel
2016
Lamivu-
dine
Control
1: ente-
cavir
Control
2: no
inter-
vention
Min 11 Low Unclear High High Low High Low Low High
Min: minimum.
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
• It was not possible to assess whether the potential effect modifiers were similar across different comparisons as this information
was missing in many trials. Therefore, we did not perform the network meta-analysis, and assessed the comparative benefits and
harms of different interventions using standard Cochrane methodology. The methodology that we plan to use if we conduct a
network meta-analysis in future is available in Appendix 1.
• We performed Trial Sequential Analysis in addition to conventional methods of assessing the risk of random errors using P values.
• We have reported seroconversion which is sometimes used as a surrogate for progression to chronic hepatitis B virus infection.
N O T E S
Considerable overlap is evident in the ’Methods’ sections of this review and those of several other reviews written by the same group of
authors.
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